{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:56:13Z","timestamp":1792842973459,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The First Affiliated Hospital of Anhui University of Science and Technology","id":[{"id":"https:\/\/ror.org\/00q9atg80","id-type":"ROR","asserted-by":"crossref"}]},{"name":"School of Medicine, Anhui University of Science and Technology","id":[{"id":"https:\/\/ror.org\/00q9atg80","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10822-025-00760-8","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:44:47Z","timestamp":1768203887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Structure-based drug design of small-molecule c-Myc G-quadruplex binders"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6723-0490","authenticated-orcid":false,"given":"Jian","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingting","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"12","key":"760_CR1","doi-asserted-by":"publisher","first-page":"E538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):E538","journal-title":"Lancet Oncol"},{"issue":"1","key":"760_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K et al (2022) NCCN guidelines insights: multiple Myeloma, version 3.2022. J Natl Compr Canc Ne 20(1):8","journal-title":"J Natl Compr Canc Ne"},{"issue":"3","key":"760_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin 74(3):229","journal-title":"Ca-Cancer J Clin"},{"key":"760_CR4","doi-asserted-by":"crossref","unstructured":"Narayanan S, Cai C-Y, Assaraf YG et al (2020) Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Update 48","DOI":"10.1016\/j.drup.2019.100663"},{"issue":"2","key":"760_CR5","first-page":"131","volume":"142","author":"S Bird","year":"2023","unstructured":"Bird S, Pawlyn C (2023) IMiD resistance in multiple myeloma: current Understanding of the underpinning biology and clinical impact. Blood 142(2):131","journal-title":"Blood"},{"issue":"10","key":"760_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1358\/dot.2021.57.10.3313853","volume":"57","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Foley N, Schroeder MA (2021) Daratumumab for the treatment of multiple myeloma. Drug Today 57(10):591","journal-title":"Drug Today"},{"key":"760_CR7","doi-asserted-by":"crossref","unstructured":"Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Csh Perspect Biol 2(1)","DOI":"10.1101\/cshperspect.a001008"},{"key":"760_CR8","doi-asserted-by":"crossref","unstructured":"Bansal R, Rakshit S, Kumar S (2021) Extramedullary disease in multiple myeloma. Blood Cancer J 11(9)","DOI":"10.1038\/s41408-021-00527-y"},{"key":"760_CR9","doi-asserted-by":"crossref","unstructured":"Llombart V, Mansour MR (2022) Therapeutic targeting of undruggable MYC. Ebiomedicine 75","DOI":"10.1016\/j.ebiom.2021.103756"},{"key":"760_CR10","doi-asserted-by":"crossref","unstructured":"Kuzyk A, Mai S (2014) c-MYC-Induced genomic instability. Csh Perspect Med 4(4)","DOI":"10.1101\/cshperspect.a014373"},{"key":"760_CR11","doi-asserted-by":"crossref","unstructured":"Carabet LA, Rennie PS, Cherkasov A (2019) Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches. Int J Mol Sci 20(1)","DOI":"10.3390\/ijms20010120"},{"key":"760_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semcancer.2020.11.008","volume":"83","author":"H Fatma","year":"2022","unstructured":"Fatma H, Maurya SK, Siddique HR (2022) Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance. Semin Cancer Biol 83:166","journal-title":"Semin Cancer Biol"},{"issue":"21","key":"760_CR13","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","volume":"117","author":"N Korde","year":"2011","unstructured":"Korde N, Kristinsson SY, Landgren O (2011) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 117(21):5573","journal-title":"Blood"},{"key":"760_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004","volume":"19","author":"G Andrieu","year":"2016","unstructured":"Andrieu G, Belkina AC, Denis GV (2016) Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today 19:45","journal-title":"Drug Discov Today"},{"issue":"6","key":"760_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","volume":"32","author":"KK Jovanovic","year":"2018","unstructured":"Jovanovic KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S (2018) Targeting MYC in multiple myeloma. Leukemia 32(6):1295","journal-title":"Leukemia"},{"issue":"6","key":"760_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/1947601910377493","volume":"1","author":"TA Brooks","year":"2010","unstructured":"Brooks TA, Hurley LH (2010) Targeting MYC expression through G-Quadruplexes. Genes Cancer 1(6):641","journal-title":"Genes Cancer"},{"issue":"9","key":"760_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/cmdc.201700747","volume":"13","author":"AR Duarte","year":"2018","unstructured":"Duarte AR, Cadoni E, Ressurreicao AS, Moreira R, Paulo A (2018) Design of modular G-quadruplex ligands. ChemMedChem 13(9):869","journal-title":"ChemMedChem"},{"key":"760_CR18","doi-asserted-by":"crossref","unstructured":"Calabrese DR, Chen X, Leon EC et al (2018) Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. Nat Commun 9","DOI":"10.1038\/s41467-018-06315-w"},{"issue":"6","key":"760_CR19","doi-asserted-by":"publisher","first-page":"e70034","DOI":"10.1111\/cbdd.70034","volume":"104","author":"J Yin","year":"2024","unstructured":"Yin J, Jia P, Qu X et al (2024) Discovery of Voreloxin as a Dual-Selective stabilizer for c-Myc\/Bcl-2 G-Quadruplexes in leukemia. Chem Biol Drug Des 104(6):e70034","journal-title":"Chem Biol Drug Des"},{"issue":"6","key":"760_CR20","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1007\/s11030-023-10789-2","volume":"28","author":"J Gao","year":"2024","unstructured":"Gao J, Liang C, Yin J, Bai Y, Hu D (2024) Discovery of Palbociclib as a potent c-Myc G4 stabilizer for lung cancer treatment using molecular docking, molecular dynamics simulation, and in vitro activity evaluation. Mol Divers 28(6):3965","journal-title":"Mol Divers"},{"issue":"1","key":"760_CR21","doi-asserted-by":"publisher","first-page":"113759","DOI":"10.1016\/j.yexcr.2023.113759","volume":"431","author":"R Yao","year":"2023","unstructured":"Yao R, Zhang Y, Zeng Y, Zhang Y, Liu L, Gao J (2023) Novel c-Myc G4 stabilizer EP12 promotes myeloma cytotoxicity by disturbing NF-\u03baB signaling. Exp Cell Res 431(1):113759","journal-title":"Exp Cell Res"},{"key":"760_CR22","doi-asserted-by":"publisher","first-page":"134673","DOI":"10.1016\/j.molstruc.2022.134673","volume":"1275","author":"X Geng","year":"2023","unstructured":"Geng X, Zhang Y, Li S et al (2023) Design, synthesis, and biological evaluation of novel Benzimidazolyl isoxazole derivatives as potential c-Myc G4 stabilizers to suppress c-Myc transcription and myeloma growth. J Mol Struct 1275:134673","journal-title":"J Mol Struct"},{"issue":"10","key":"760_CR23","doi-asserted-by":"publisher","first-page":"e2200011","DOI":"10.1002\/minf.202200011","volume":"41","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wang T, Geng X, Liu L, Gao J (2022) Identification of trovafloxacin, ozanimod, and ozenoxacin as potent c-Myc G-quadruplex stabilizers to suppress c-Myc transcription and myeloma growth. Mol Inf 41(10):e2200011","journal-title":"Mol Inf"},{"issue":"4","key":"760_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/cbdd.14064","volume":"100","author":"L Liu","year":"2022","unstructured":"Liu L, Geng X, Zhang J, Li S, Gao J (2022) Structure-based discovery of licoflavone B and Ginkgetin targeting c-Myc G-quadruplex to suppress c-Myc transcription and myeloma growth. Chem Biol Drug Des 100(4):525","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"760_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1158\/0008-5472.CAN-04-2910","volume":"65","author":"AM Burger","year":"2005","unstructured":"Burger AM, Dai F, Schultes CM et al (2005) The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res 65(4):1489","journal-title":"Cancer Res"},{"key":"760_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lfs.2024.122481","volume":"340","author":"J Figueiredo","year":"2024","unstructured":"Figueiredo J, Mergny JL, Cruz C (2024) G-quadruplex ligands in cancer therapy: Progress, challenges, and clinical perspectives. Life Sci 340:14","journal-title":"Life Sci"},{"key":"760_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1134\/S1068162024010242","volume":"151","author":"R Wang","year":"2024","unstructured":"Wang R, Hu MH (2024) Development of a fluorescent ligand that specifically binds to the c-MYC G-quadruplex by migrating the benzene group on a carbazole-benzothiazolium scaffold. Bioorg Chem 151:8","journal-title":"Bioorg Chem"},{"issue":"26","key":"760_CR28","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1039\/D5CC00098J","volume":"61","author":"R Wang","year":"2025","unstructured":"Wang R, Hu MH (2025) AIE and UIA-featured fluorescent ligands for G-quadruplex: the impact of linker rigidity between recognition moiety and fluorophore. Chem Commun 61(26):4991","journal-title":"Chem Commun"},{"issue":"16","key":"760_CR29","doi-asserted-by":"publisher","first-page":"9397","DOI":"10.1093\/nar\/gkae649","volume":"52","author":"WT Liu","year":"2024","unstructured":"Liu WT, Zhu BC, Liu LY et al (2024) Solution structures and effects of a platinum compound successively bound MYC G-quadruplex. Nucleic Acids Res 52(16):9397","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"760_CR30","first-page":"11","volume":"31","author":"RN Das","year":"2025","unstructured":"Das RN, Chorell E (2025) Design, Synthesis, and biophysical characterization of pyridine Bis-Quinazoline derivatives as selective G-Quadruplex DNA stabilizers. Chem-Eur J 31(21):11","journal-title":"Chem-Eur J"},{"issue":"1","key":"760_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijms25010623","volume":"25","author":"S Cao","year":"2024","unstructured":"Cao S, Su Q, Chen YH et al (2024) Molecular insights into the specific targeting of c-MYC G-Quadruplex by thiazole peptides. Int J Mol Sci 25(1):20","journal-title":"Int J Mol Sci"},{"issue":"3","key":"760_CR32","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1021\/acs.jmedchem.3c02127","volume":"67","author":"M Andreasson","year":"2024","unstructured":"Andreasson M, Donzel M, Abrahamsson A et al (2024) Exploring the dispersion and electrostatic components in Arene-Arene interactions between ligands and G4 DNA to develop G4-Ligands. J Med Chem 67(3):2202","journal-title":"J Med Chem"},{"issue":"10","key":"760_CR33","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1021\/ja017308q","volume":"124","author":"M-Y Kim","year":"2002","unstructured":"Kim M-Y, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH (2002) Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc 124(10):2098","journal-title":"J Am Chem Soc"},{"issue":"8","key":"760_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/molecules30081805","volume":"30","author":"JH Lin","year":"2025","unstructured":"Lin JH, Gong Z, Lu YY et al (2025) Recent progress and potential of G4 ligands in cancer immunotherapy. Molecules 30(8):23","journal-title":"Molecules"},{"issue":"1","key":"760_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-021-01328-4","volume":"20","author":"N Kosiol","year":"2021","unstructured":"Kosiol N, Juranek S, Brossart P, Heine A, Paeschke K (2021) G-quadruplexes: a promising target for cancer therapy. Mol Cancer 20(1):18","journal-title":"Mol Cancer"},{"issue":"44","key":"760_CR36","doi-asserted-by":"publisher","first-page":"17673","DOI":"10.1021\/ja205646q","volume":"133","author":"J Dai","year":"2011","unstructured":"Dai J, Carver M, Hurley LH, Yang D (2011) Solution structure of a 2:1 Quindoline-c-MYC G-Quadruplex: insights into G-Quadruplex-Interactive small molecule drug design. J Am Chem Soc 133(44):17673","journal-title":"J Am Chem Soc"},{"issue":"5","key":"760_CR37","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers D, Hahn M (2010) Extended-connectivity fingerprints. J Chem Inf Model 50(5):742","journal-title":"J Chem Inf Model"},{"key":"760_CR38","doi-asserted-by":"crossref","unstructured":"Bajusz D, Racz A, Heberger K (2015) Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J Cheminformatics 7","DOI":"10.1186\/s13321-015-0069-3"},{"issue":"7","key":"760_CR39","doi-asserted-by":"publisher","first-page":"12036","DOI":"10.1021\/acsomega.9b01142","volume":"4","author":"L Cai","year":"2019","unstructured":"Cai L, Qin X, Xu Z et al (2019) Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method. Acs Omega 4(7):12036","journal-title":"Acs Omega"},{"issue":"3","key":"760_CR40","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi C, Nicoletti I (2006) Analysis of apoptosis by Propidium iodide staining and flow cytometry. Nat Protoc 1(3):1458","journal-title":"Nat Protoc"},{"key":"760_CR41","doi-asserted-by":"crossref","unstructured":"Taylor SC, Posch A (2014) The design of a quantitative Western Blot experiment. Biomed Res Int 2014","DOI":"10.1155\/2014\/361590"},{"issue":"4","key":"760_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method. Methods 25(4):402","journal-title":"Methods"},{"issue":"3","key":"760_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nchem.1548","volume":"5","author":"G Biffi","year":"2013","unstructured":"Biffi G, Tannahill D, McCafferty J, Balasubramanian S (2013) Quantitative visualization of DNA G-quadruplex structures in human cells. Nat Chem 5(3):182","journal-title":"Nat Chem"},{"issue":"2","key":"760_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/1439-7633(20010202)2:2<124::AID-CBIC124>3.0.CO;2-L","volume":"2","author":"JL Mergny","year":"2001","unstructured":"Mergny JL, Maurizot JC (2001) Fluorescence resonance energy transfer as a probe for G-quartet formation by a telomeric repeat. ChemBioChem 2(2):124","journal-title":"ChemBioChem"},{"issue":"12","key":"760_CR45","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1093\/nar\/gks152","volume":"40","author":"JM Nicoludis","year":"2012","unstructured":"Nicoludis JM, Barrett SP, Mergny JL, Yatsunyk LA (2012) Interaction of human telomeric DNA with N-methyl mesoporphyrin IX. Nucleic Acids Res 40(12):5432","journal-title":"Nucleic Acids Res"},{"key":"760_CR46","unstructured":"Case DA, Ben-Shalom IY, Brozell SR et al (2018) AMBER 2018 reference manual"},{"issue":"1","key":"760_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nmeth.3658","volume":"13","author":"I Ivani","year":"2016","unstructured":"Ivani I, Dans PD, Noy A et al (2016) Parmbsc1: a refined force field for DNA simulations. Nat Methods 13(1):55","journal-title":"Nat Methods"},{"issue":"9","key":"760_CR48","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157","journal-title":"J Comput Chem"},{"issue":"16","key":"760_CR49","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/jcc.10128","volume":"23","author":"A Jakalian","year":"2002","unstructured":"Jakalian A, Jack DB, Bayly CI (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 23(16):1623","journal-title":"J Comput Chem"},{"issue":"3","key":"760_CR50","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1021\/acs.jctc.8b01039","volume":"15","author":"D Vassetti","year":"2019","unstructured":"Vassetti D, Pagliai M, Procacci P (2019) Assessment of GAFF2 and OPLS-AA general force fields in combination with the water models TIP3P, SPCE, and OPC3 for the solvation free energy of druglike organic molecules. J Chem Theory Comput 15(3):1983","journal-title":"J Chem Theory Comput"},{"issue":"7","key":"760_CR51","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE III (2013) PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9(7):3084","journal-title":"J Chem Theory Comput"},{"issue":"5","key":"760_CR52","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Dis 10(5):449","journal-title":"Expert Opin Drug Dis"},{"key":"760_CR53","doi-asserted-by":"crossref","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep-Uk 7","DOI":"10.1038\/srep42717"},{"key":"760_CR54","doi-asserted-by":"crossref","unstructured":"Xu H, Hurley LH (2022) A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex). Bioorg Med Chem Lett 77","DOI":"10.1016\/j.bmcl.2022.129016"},{"key":"760_CR55","doi-asserted-by":"crossref","unstructured":"Bahls B, Aljnadi IM, Emidio R, Mendes E, Paulo A (2023) G-Quadruplexes in c-MYC promoter as targets for cancer therapy. Biomed Res Int 11(3)","DOI":"10.3390\/biomedicines11030969"},{"issue":"1","key":"760_CR56","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/molecules20010206","volume":"20","author":"R Rocca","year":"2015","unstructured":"Rocca R, Moraca F, Costa G et al (2015) Structure-based virtual screening of novel natural alkaloid derivatives as potential binders of h-telo and c-myc DNA G-Quadruplex conformations. Molecules 20(1):206","journal-title":"Molecules"},{"key":"760_CR57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.biochi.2018.06.024","volume":"152","author":"RC Monsen","year":"2018","unstructured":"Monsen RC, Trent JO (2018) G-quadruplex virtual drug screening: a review. Biochimie 152:134","journal-title":"Biochimie"},{"issue":"2","key":"760_CR58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ymeth.2006.10.004","volume":"42","author":"A De Cian","year":"2007","unstructured":"De Cian A, Guittat L, Kaiser M et al (2007) Fluorescence-based melting assays for studying quadruplex ligands. Methods 42(2):183","journal-title":"Methods"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00760-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00760-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00760-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:01:58Z","timestamp":1768248118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00760-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00760-8","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"46"}}